DGAP-News

CEVEC's CAP(R)Go derived recombinant placental human alkaline phosphatase shows superior results in a preclinical study - Seite 2

lead to a reduction in effective dosage and frequency of administration;
two important factors that pose a challenge in chronic indications.
Together with the outstanding CAP(R)Go production capabilities of up to 10
fold higher yields than conventional cell lines this new cell line enables
the development of a highly efficacious and economic alkaline phosphatase
based therapy. CEVEC plans to partner the further development of the
molecule.

"The results with the recombinant placental human alkaline phosphatase
show, once again, the potential of our recently launched proprietary
CAP(R)Go technology," commented Frank Ubags, Chief Executive Officer of
CEVEC Pharmaceuticals GmbH. "The CAP(R)Go expression platform has already
been shown to enhance the activity, stability and serum half-life of the
recombinant C1 Inhibitor. Promising projects on other complex recombinant
glycoproteins are progressing."

About CEVEC:

Privately held CEVEC, based in Cologne, Germany, is an expert for the
production of tailor-made recombinant glyco-proteins and gene therapy
vectors. The Company's core technologies, CAP(R)Go and CAP(R)GT are based
on a unique human cellular expression system.

The CAP(R)Go expression platform comprises a portfolio of glyco-optimized
human suspension cell lines for tailor-made glycosylation of recombinant
proteins. The cells are highly efficient for the production of a broad
range of difficult to express glycoproteins and provide authentic human
post-translational modifications. CAP(R)Go has proven to enhance the
activity, stability and serum half-life of several candidate proteins.

The CAP(R)GT expression platform provides a fully scalable, regulatory
endorsed production system for gene therapy vectors. CAP(R)GT cells grow to
high cell densities and show a broad viral propagation spectrum including
lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Furthermore, CAP(R)GT enables easier scale-up and reduced production costs
when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology
partners followed by licensing agreements for the technology form one
revenue base for CEVEC. In addition, the Company provides contract
manufacturing for the cGMP production in CAP(R)Go and CAP(R)GT cells.

Contact:

CEVEC Pharmaceuticals GmbH                 MC Services AG
Frank Ubags                                Anne Hennecke
Chief Executive Officer                    Public Relations
T.:[phone]                        T.: [phone]
E.: [e-mail]                        E.: [e-mail]

www.cevec.com



---------------------------------------------------------------------

06.07.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


375257 06.07.2015